EUVIMEDEUVIMED entdecken
Open Access

The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma

Matthew McCord, Thomas Sears, Wenxia Wang, Rahul Chaliparambil, Shejuan An, Jann Sarkaria, C David James, Bruce Ruggeri, Susan Gueble, Ranjit Bindra iD, Craig Horbinski iD

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Matthew McCord und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA. Hauptthemen laut MEDLINE: Glioblastoma, Temozolomide, DNA Mismatch Repair, Brain Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acquired resistance to temozolomide (TMZ) chemotherapy due to DNA mismatch repair (MMR) enzyme deficiency is a barrier to improving outcomes for isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) patients. KL-50 is a new imidazotetrazine-based therapeutic designed to induce DNA interstrand cross-links, and subsequent double-stranded breaks, in an MMR-independent manner in cells with O-6-methylguanine-DNA methyltransferase (MGMT) deficiency. Previous research showed its efficacy against LN229 glioma cells with MMR and MGMT knockdown. Its activity against patient-derived GBM that model post-TMZ recurrent tumors is unclear.

Methods

We created MMR-deficient GBM patient-derived xenografts through exposure to TMZ, followed by treatment with additional TMZ or KL-50. We also generated isogenic, MSH6 knockout (KO) patient-derived GBM and tested them for sensitivity to TMZ and KL-50.

Results

KL-50 extended the median survival of mice intracranially engrafted with either patient-derived TMZ-naïve GBM6 or TMZ-naïve GBM12 by 1.75-fold and 2.15-fold, respectively (P < 0.0001). A low dose (4 Gy) of fractionated RT further extended the survival of KL-50-treated GBM12 mice (median survival = 80 days for RT + KL-50 vs. 71 days KL-50 alone, P = 0.018). KL-50 also extended the median survival of mice engrafted with post-TMZ, MMR-deficient GBM6R-m185 (140 days for KL-50 vs. 37 days for vehicle, P < 0.0001). MSH6 KO increased TMZ IC50 for GBM6 and GBM12 cultures by >5-fold and >12-fold for cell death and live cell count outputs, respectively. In contrast, MSH6-KO actually decreased KL-50 IC50 by 10–80%.

Conclusion

KL-50-based compounds are a promising new strategy for the treatment of MGMT-deficient, MMR-deficient GBM that recurs after frontline TMZ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTemozolomideDNA Mismatch RepairBrain NeoplasmsNeoplasm Recurrence, LocalCross-Linking ReagentsAnimalsHumansMiceXenograft Model Antitumor AssaysAntineoplastic Agents, AlkylatingTumor Cells, CulturedFemaleDNA-Binding Proteins

Stichwörter der Autor:innen

KL-50glioblastomamismatch repairrecurrenttemozolomide

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingCross-Linking ReagentsG-T mismatch-binding proteinDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
  • ModifiBio, New Haven, CT, USA.
  • Department of Therapeutic Radiology, Yale University, New Haven, CT, USA.
  • Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

ORCID-Profile: Ranjit Bindra, Craig Horbinski

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

McCord, M., Sears, T., Wang, W., Chaliparambil, R., An, S., Sarkaria, J., James, C. D., Ruggeri, B., Gueble, S., Bindra, R., & Horbinski, C. (2025). The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae257

Vancouver

McCord M, Sears T, Wang W, Chaliparambil R, An S, Sarkaria J, et al. The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae257

BibTeX
@article{McCord2025,
  author = {McCord, Matthew and Sears, Thomas and Wang, Wenxia and Chaliparambil, Rahul and An, Shejuan and Sarkaria, Jann and James, C David and Ruggeri, Bruce and Gueble, Susan and Bindra, Ranjit and Horbinski, Craig},
  title = {The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae257}
}
Kostenlos starten →